The interplay between sacubitril/valsartan, heart failure with preserved ejection fraction, diabetes and kidney function

被引：4
|
作者：
Voordes, Geert H. D. [1 ]
Heerspink, Hiddo J. L. [2 ]
ter Maaten, Jozine M. [1 ]
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2022年 / 24卷 / 05期
关键词：
LCZ696;
D O I：
10.1002/ejhf.2501
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：804 / 806
页数：3
相关论文
共 50 条
  • [1] Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction
    Butt, Jawad H.
    Dewan, Pooja
    Jhund, Pardeep S.
    Anand, Inder S.
    Atar, Dan
    Ge, Junbo
    Desai, Akshay S.
    Echeverria, Luis E.
    Kober, Lars
    Lam, Carolyn S. P.
    Maggioni, Aldo P.
    Martinez, Felipe
    Packer, Milton
    Rouleau, Jean L.
    Sim, David
    Van Veldhuisen, Dirk J.
    Vrtovec, Bojan
    Zannad, Faiez
    Zile, Michael R.
    Gong, Jianjian
    Lefkowitz, Martin P.
    Rizkala, Adel R.
    Solomon, Scott D.
    McMurray, John J., V
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 80 (12) : 1130 - 1143
  • [2] Sacubitril/valsartan in an experimental model of heart failure with preserved ejection fraction
    De Angelis, A.
    Cappetta, D.
    Telesca, M.
    Bellocchio, G.
    Urbanek, K.
    Berrino, L.
    CARDIOVASCULAR RESEARCH, 2022, 118 (SUPPL 1)
  • [3] Sacubitril/Valsartan in heart failure with preserved ejection fraction in women and lower-range preserved ejection fraction
    Dachs, T.
    Nagele, F.
    Rettl, R.
    Dalos, D.
    Duca, F.
    Binder-Rodriguez, C.
    Camuz-Ligios, L.
    Dusik, F.
    Seirer, B.
    Hengstenberg, C.
    Bonderman, D.
    WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : S206 - S207
  • [4] Distinct Effects of Sacubitril/Valsartan on Left Atrial Function Between Heart Failure With Preserved and Reduced Ejection Fraction
    Hashimoto, Takaaki
    Hashimoto, Kaho
    Iijima, Aika
    Karasawa, Yuka
    Amano, Kazushige
    Hama, Tomoaki
    Fujii, Toshiharu
    Kawamura, Youta
    Ushijima, Akiko
    Yoshimachi, Fuminobu
    Morita, Norishige
    Murata, Mitsushige
    CIRCULATION, 2023, 148
  • [5] Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
    Selvaraj, Senthil
    Claggett, Brian L.
    Packer, Milton
    Zannad, Faiez
    Anand, Inder S.
    Pieske, Burkert
    Zhao, Ziqiang
    Shi, Victor C.
    Lefkowitz, Martin P.
    McMurray, John J., V
    Solomon, Scott D.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (17):
  • [6] Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction
    Jia, Ruoyu
    Ji, Ying
    Sun, Dong
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 155
  • [7] Targeting sacubitril/valsartan for heart failure with mildly reduced or preserved ejection fraction
    Greene, Stephen J.
    Fonarow, Gregg C.
    EUROPEAN HEART JOURNAL, 2023, 44 (31) : 2994 - 2997
  • [8] Making the case for sacubitril/valsartan in patients with heart failure with a preserved ejection fraction
    Tai, Andrew
    Ambrosy, Andrew P.
    Fudim, Marat
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2021, 7 (03) : E5 - E6
  • [9] Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction
    Raschi, Emanuel
    Diemberger, Igor
    Sabatino, Mario
    Poluzzi, Elisabetta
    De Ponti, Fabrizio
    Potena, Luciano
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (03) : 303 - 320
  • [10] The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction
    Gronda, Edoardo
    Vanoli, Emilio
    Iacoviello, Massimo
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0L) : L77 - L81
12345